

IN THE CLAIMS

Please amend the claims as follows. This listing of claims replaces all prior versions.

1-37. (Canceled).

38. (Currently amended) A method of ~~diagnosing schizophrenia and/or affective psychosis or identifying a human subject as having susceptibility to schizophrenia and/or affective psychosis in an individual~~, wherein the method comprises determining if the *GRIK4* gene in the ~~individual~~human subject has been disrupted by a mutation or chromosomal rearrangement, wherein a determination that the *GRIK4* gene in the subject has been disrupted by a mutation or chromosomal rearrangement identifies the subject as having susceptibility to schizophrenia and/or affective psychosis.

39. (Previously presented) The method according to claim 38, wherein any disruption is determined by detecting a relative level of mRNA expressed by the *GRIK4* gene.

40. (Previously presented) The method according to claim 38, wherein a level of the *GRIK4* gene product is detected by an immunological technique.

41. (Previously presented) The method according to claim 40, wherein an antibody or antibodies specific for *GRIK4* gene is/are used to detect said gene product(s).

42-45. (Canceled).

46. (Previously presented) The method of claim 38, wherein the mutation or chromosomal rearrangement is detected using high-throughput fluorescence *in situ* hybridization (FISH).

47. (Previously presented) The method of claim 38, wherein the mutation or chromosomal

rearrangement is detected using oligonucleotides designed to hybridize to the *GRIK4* gene.

48. (Previously presented) The method of claim 47, wherein the oligonucleotides are labeled.

49. (Withdrawn) The method of claim 38, further comprising determining if the *SEMCAP3*, *N33*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s) in an individual has/have been disrupted by a mutation or chromosomal rearrangement.

50. (Withdrawn) The method of claim 49, wherein the mutation or chromosomal rearrangement in the *SEMCAP3*, *N33*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s), is detected using high-throughput fluorescence *in situ* hybridization (FISH).

51. (Withdrawn) The method of claim 49, wherein the mutation or chromosomal rearrangement in the *SEMCAP3*, *N33*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s), is detected using oligonucleotides designed to hybridize to the *SEMCAP3*, *N33*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s).

52. (Withdrawn) The method of claim 51, wherein the oligonucleotides are labeled.

53. (Withdrawn) The method of claim 49, wherein any disruption is determined by detecting a relative level of mRNA expressed by the *SEMCAP3*, *N33*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s).

54. (Withdrawn) The method according to claim 53, wherein a level of the *SEMCAP3*, *N33*,

ATTORNEY DOCKET NO. 9013-63

Application Serial No. 10/511,455

Page 10 of 21

NPAS2, *PDE4B* and/or *CDH8* gene products is detected by an immunological technique.

55. (Withdrawn) The method according to claim 54, wherein an antibody or antibodies specific for the/said gene(s) is used to detect said gene product.